Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Harvard Business School
Colorcon
Baxter

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AT7519

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug AT7519: Patents, clinical trial progress, indications

AT7519 is an investigational drug.

There have been 5 clinical trials for AT7519. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Lymphoma, Leukemia, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Astex Pharmaceuticals, NCIC Clinical Trials Group, and National Cancer Institute (NCI).

There are twenty-two US patents protecting this investigational drug and two hundred and twenty-eight international patents.

Recent Clinical Trials for AT7519
TitleSponsorPhase
Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 1
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic LeukemiaAstex PharmaceuticalsPhase 2
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic LeukemiaNCIC Clinical Trials GroupPhase 2

See all AT7519 clinical trials

Clinical Trial Summary for AT7519

Top disease conditions for AT7519
Top clinical trial sponsors for AT7519

See all AT7519 clinical trials

US Patents for AT7519

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AT7519   See Pricing Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   See Pricing
AT7519   See Pricing Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   See Pricing
AT7519   See Pricing Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Dow
AstraZeneca
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.